Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the three and six months ended June 30, 2000. Gilead is an independent biopharmaceutical company focused on infectious diseases and cancer. Key marketed products include AmBisome (antifungal), DaunoXome (Kaposi's Sarcoma), and VISTIDE (CMV retinitis). The company operates under a pooling of interests with NeXstar Pharmaceuticals, Inc., acquired in July 1999, requiring restatement of 1999 comparative data.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2000 | Six Months Ended June 30, 2000 | Six Months Ended June 30, 1999 |
|---|---|---|---|
| Total Revenues | $49.98 million | $95.20 million | $81.81 million |
| Net Loss | $(4.19) million | $(9.95) million | $(27.17) million |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.22) | $(0.65) |
| Operating Loss | $(5.79) million | $(12.73) million | $(28.92) million |
| Research & Development | $27.25 million | $53.31 million | $52.14 million |
| Cash & Cash Equivalents | $42.74 million | $42.74 million (End of Period) | $115.95 million (End of Period) |
| Marketable Securities | $252.81 million | $252.81 million (End of Period) | $247.38 million (End of Period) |
| Total Liquidity (Cash + Securities) | $295.55 million | $295.55 million | $363.33 million |
| Convertible Debt | $79.51 million | $79.51 million | $79.53 million |
Revenue Composition (Six Months 2000): Product sales ($74.33M), Royalties ($15.72M), Contract revenues ($5.15M). AmBisome accounted for approximately 95% of product sales.
Material Changes vs. Prior Period
- Profitability Improvement: Net loss for the six months ended June 30, 2000, decreased significantly to $9.95 million from $27.17 million in the prior year period. Operating loss narrowed to $12.73 million from $28.92 million.
- Revenue Growth: Total revenues increased 16% year-over-year for the six-month period, driven primarily by a 222% increase in royalty revenues (largely due to Tamiflu royalties from Roche) and a 13% increase in product sales.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased to $38.0 million from $44.1 million, attributed to the elimination of duplicate functions following the NeXstar merger and the absence of merger-related expenses recorded in 1999.
- Cash Flow: Net cash used in operating activities improved dramatically to $5.03 million from $31.76 million used in the prior year. However, investing activities consumed $13.92 million due to net purchases of marketable securities.
Outlook, Risks, and Unusual Items
- Debt Conversion (Subsequent Event): In August 2000, the entire $79.5 million principal amount of 6.25% convertible subordinated debentures was converted into approximately 1.78 million shares of common stock. This eliminates a significant portion of interest expense for the remainder of the year.
- Product Discontinuation: Gilead discontinued the development of MiKasome (liposomal amikacin) after evaluating pre-clinical and clinical data, determining it did not support continued development.
- Collaboration Milestones: The company received a $7.0 million up-front fee from EyeTech Pharmaceuticals for NX 1838 (ophthalmic aptamer), with $1.7 million recognized in Q2 2000. Potential future milestone payments include up to $25.0 million from EyeTech and $19.2 million from Roche.
- Tamiflu Regulatory Status: Roche withdrew its European application for Tamiflu to submit further data; marketing in Europe for the 2000-2001 flu season is not expected. An application was filed in Japan in August 2000.
- Foreign Currency Risk: A significant portion of sales is denominated in foreign currencies. A stronger U.S. dollar negatively impacts reported revenues and gross margins. Past due receivables in Greece, Spain, and Italy totaled $17.3 million, with $7.7 million over 120 days past due.
- Profitability Warning: Management states the company has never been profitable on a full-year basis and may never achieve or sustain profitability. Accumulated deficit stands at $459.2 million.
Investor Verification Checklist
- Debt Elimination: Confirm the impact of the $79.5 million debt conversion on Q3 and Q4 interest expense and share count dilution.
- Receivables Quality: Assess the collectibility of the $17.3 million in past due receivables from Greece, Spain, and Italy, particularly the $7.7 million over 120 days old.
- Tamiflu Royalties: Monitor the resubmission of the European Tamiflu application and the timing of future royalty recognition from Roche.
- AmBisome Pricing: Verify trends in average selling prices and currency impacts on the company's primary revenue driver (AmBisome).
- R&D Pipeline: Track progress on tenofovir disoproxil fumarate (HIV) and adefovir dipivoxil (HBV), which are the primary drivers of current R&D spending.